New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans
Sign Up to like & getrecommendations! Published in 2022 at "Platelets"
DOI: 10.1080/09537104.2022.2088719
Abstract: Abstract BMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) antagonist exhibiting robust antithrombotic activity that has shown low bleeding risk in monkeys. We sought to assess pharmacokinetics, pharmacodynamics, and tolerability of BMS-986120 in… read more here.
Keywords: bms 986120; protease activated; par4; oral protease ... See more keywords